课题基金 / 基金详情

The role of a histone point mutation in pediatric gliomagenesis

The role of a histone point mutation in pediatric gliomagenesis
组蛋白点突变在儿童胶质瘤发生中的作用
批准号:
10403594
负责人:
Kasey R Skinner
金额:
$4.11万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-29 至 2023-06-28
关键词:

项目摘要

项目成果

Kasey R Skinner的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
PROJECT SUMMARY Pediatric high-grade gliomas (pHGG) are the most common and malignant primary brain tumors in children. Mutations in H3F3A, one of the genes that encodes histone variant H3.3, are definitional for pHGG and H3.3 mutation status correlates with clinical variables such as survival and tumor location. pHGG with a lysine 27 to methionine substitution (H3.3K27M) occur in the brain stem and correlate with particularly poor survival. H3.3K27M is insufficient to drive tumorigenesis in mouse models. However, it co-occurs in humans with PDGFRA activation and TP53 and ATRX deletion, suggesting that H3.3K27M cooperates with these oncogenic mutations to induce tumors. Further, the phenotypic differences between H3.3K27M pHGG and other pHGG suggest differing epigenetic alterations and mechanisms of tumorigenesis. This proposal is focused on identifying the epigenetic and transcriptomic changes induced in murine neural stem cells (NSC) by H3.3K27M and its co-occurring mutations and how those mutations lead to glioma cell phenotypes. To model H3.3K27M pHGG as accurately as possible, I will use an RCAS-TVA-based model in which NSC harvested from Nestin tv-a; Trp53fl/fl or Nestin tv- a; Trp53fl/fl; Atrxfl/fl mice are infected with RCAS viruses encoding Cre recombinase, PDGFβ, and H3.3K27M. The resulting NSC will be used to characterize the global and local epigenetic and transcriptomic changes induced by H3.3K27M and its co-occurring mutations in NSC using western blots, ChIP-seq, and RNA-seq. Further, I will characterize the phenotypic changes caused by these alterations using immunocytochemistry, extreme limiting dilution, proliferation assays, and orthotopic allografts. Finally, I will validate the epigenetic and transcriptomic signatures of H3.3K27M mouse NSC in a panel of H3.3WT and H3.3K27M patient derived xenograft (PDX) cell lines via ChIP-seq and RNA-seq, as well as with existing datasets from human tumor samples. These studies will identify mechanisms of pathogenesis for H3.3K27M pHGG and potential epigenetic therapeutic targets that are both tractable in mice and relevant to humans. By completing this research proposal, I will gain technical skills applicable to cancer biology, neuroscience, epigenetics, and biochemistry while also developing my critical thinking, scientific communication, and ethical research skills.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
绘制未知领域:精准胶质母细胞瘤治疗的基因表达特征。
DOI: 10.1093/neuonc/noaa242
发表时间: 2020
期刊: Neuro-oncology
影响因子: 15.9
作者: [Skinner,KaseyR, Nabors,LBurt, Miller,CRyan]
通讯作者: Miller,CRyan
The role of a histone point mutation in pediatric gliomagenesis
海外基金